Press Release Categories

    Urinary Incontinence Market was found to be USD 3.6 Billion in 2016 in 7MM
    03 Oct, 2017

    Urinary Incontinence is a multifactorial syndrome which occurs due to the failure of the storage function of the lower urinary tract and loss of bladder control resulting in leakage of urine.  Embarrassment, isolation, and depression are observed among patients with Urinary Incontinence. Millions of individuals worldwide are suffering from Urinary Incontinence. It is most common among the old people.  It increases the chances of developing several medical conditions such as local skin irritation, rashes, and urinary infections.

    Urinary Incontinence is classified as Stress Incontinence, Urge Incontinence, Overflow Incontinence, Functional Incontinence, Mixed Incontinence, Transient Incontinence, Total Incontinence and Reflex Incontinence.

    DiligentMarket estimate suggest that, population at risk of Urinary Incontinence was found to be more than 93 Million in 2016 for 7MM.

    Complete Report link @

    Provides overview of the Urinary Incontinence, pathophysiology, diagnostic approaches and treatment algorithm including detailed chapters for marketed products as well as emerging therapies. Pipeline analysis across (PhaseIII), emerging trends and comparative analysis of pipeline products with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with product development activities.

    Report provides historical as well as forecasted epidemiology of Urinary Incontinence in the 7MM covering United States and EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan from 2015-2025. Report also covers the detailed historical and forecasted Urinary Incontinence covering United States and EU5 countries from 2015-2025.

    Increasing obese and older population are major factors leading to increase in prevalent cases of Urinary Incontinence. EU5 accounts for the maximum number of Urinary Incontinence patients, followed by United States and Japan.

    Based on the classification of Urinary Incontinence, Stress Urinary Incontinence contributes the major share of the Urinary Incontinence as compared to the subtypes in the 7MM, expect for France where Mixed Incontinence contributes the major share.

    DiligentMarket estimates that the prevalent population of Urinary Incontinence will significantly increase at a CAGR of 0.45% for the forecasted period i.e. 2015-2025 in 7 major markets.

    Prevalent Population of Urinary Incontinence in 7MM (2016) 

    Prevalent Population of Urinary Incontinence in 7MM (2025)

    Some of the key findings are –

    • The Market size of Urinary Incontinence was found to be USD 3.6 Billion in 2016 in 7MM.
    • Increase in the drug under pipeline for Urinary incontinence screening tests is one of the major drivers for the Urinary incontinence therapeutics market globally.
    • Further increase in the growth rate is expected due to upcoming Urinary Incontinence therapies which will be launched in 2017 (ICES13), 2018 (Mirabegron+solifenacin and Vibegron), in 2021 (Autologous Muscle Derived Cell Transplantation), and in 2025 (AbobotulinumtoxinA) is expected to drive additional growth within this market.

    Urinary incontinence therapeutics market is driven by the patient pool of age 40 & above thereby prevalent cases of UI in young women are comparatively less than that of older age groups, with increasing age the condition become more severe which indirectly increase the market size. The prevalence rate of urinary incontinence in adult men is expected to be 5-6%, and most of the male cases are related to prostate diseases. The prevalence of stress and mixed incontinence is higher than urge incontinence in 7MM.

    Mirabegron is a beta-3 adrenergic agonist. It works by relaxing muscles in the bladder and treating overactive bladder with symptoms of an urgent need to urinate. It was developed by Astellas Pharma and was approved in the United States in July 2012. Botox (onabotulinumtoxinA) from Allergan was approved in January 2013 by FDA to treat overactive bladder symptoms such as a strong need to urinate with leaking or wetting accidents. Market revenue growth has been seen from the recent years and expected to increase in the forecasted year for this drug.

    The United States had the largest market share in 2016, followed by Japan and Germany among 7MM. Spain had the lowest market share.

    According to DiligentMarket, a higher growth has been seen in the Urinary Incontinence market during the forecast period. The market is estimated to grow at a CAGR of 9.5% from 2015-2025.

    Geographic-specific trends are observed for the different marketed products, as United States accounts for the highest market size of Urinary Incontinence as compared to EU5 countries (United Kingdom, Germany, Spain, and Italy) and Japan.

    The market analysis study is carried out for the period of 2015-2025. With respect to that, the Urinary Incontinence Global Market Size was estimated at USD 3.6 Billion in 2016.

     Total Market Size of Urinary Incontinence in 7MM (2015-2025)

    further information or queries, please contact the Sales Team, DiligentMarket at or

    About DiligentMarket –

    DiligentMarket is a Business Consultant company and serve as a Knowledge partner across the value chain of Pharmaceutical Industry. With the use of proprietary databases and analytical models, DiligentMarket provides cutting-edge market and pipeline analysis and API intelligence across all therapy areas to the Pharma and biotech sector, helping clients to quantify market events and evaluate their impact on the valuation of products, portfolios and companies. Additional information is available at